LATANOPROSTENE BUNOD


Trade Names	VYZULTA
Synonyms	BOL-303259-X Bol-303259-x Latanoprostene bunod NCX 116 NCX-116 PF-3187207 Vesneo Vyzulta
Status
Molecule Category	UNKNOWN
ATC	S01EE06
UNII	I6393O0922


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	LOVMMUBRQUFEAH-UIEAZXIASA-N
Smiles	O=C(CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O)OCCCCO[N+](=O)[O-]
InChI	InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C27H41NO8
Molecular Weight	507.62
AlogP	3.77
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	18.0
Polar Surface Area	139.36
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	36.0

Bioactivity

Mechanism of Action	Action	Reference
Prostanoid FP receptor agonist	AGONIST	PubMed PubMed Other


Protein: Prostanoid FP receptor Description: Prostaglandin F2-alpha receptor Organism : Homo sapiens P43088 ENSG00000122420

Related Entries

Cross References

Resources	Reference
ChEMBL	CHEMBL2364612
DrugBank	DB11660
DrugCentral	5261
FDA SRS	I6393O0922
Guide to Pharmacology	9635
PubChem	11156438
SureChEMBL	SCHEMBL12119560
ZINC	ZINC000095598449

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).